A historical perspective of liposomes-a bio nanomaterial

Sharma, Vikash; Agrawal, Manoj Kumar

doi:10.1016/j.matpr.2020.11.952

Cited by 28 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Liposomes have been assessed as drug delivery vehicles since the 1970s. 46 Therefore, substantial literature exists on the interactions between liposomes and biological nanoparticles, including EVs and lipoproteins. Liposomes are composed of an aqueous core surrounded by multi-or unilamellar phospholipid bilayers, which unlike EVs, usually lack other surface biomolecules, such as proteins and glycans.…”

Section: Interactionsmentioning

confidence: 99%

“…Liposomes are synthetic lipid-based nanoparticles that represent the largest category of clinically approved nanoparticles . Liposomes have been assessed as drug delivery vehicles since the 1970s . Therefore, substantial literature exists on the interactions between liposomes and biological nanoparticles, including EVs and lipoproteins.…”

Section: Lessons Learned From Liposome Interactionsmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicle and Lipoprotein Interactions

Ghebosu,

Pendiuk Goncalves,

Wolfram

2023

Nano Lett.

View full text Add to dashboard Cite

Extracellular vesicles and lipoproteins are lipid-based biological nanoparticles that play important roles in (patho)physiology. Recent evidence suggests that extracellular vesicles and lipoproteins can interact to form functional complexes. Such complexes have been observed in biofluids from healthy human donors and in various in vitro disease models such as breast cancer and hepatitis C infection. Lipoprotein components can also form part of the biomolecular corona that surrounds extracellular vesicles and contributes to biological identity. Potential mechanisms and the functional relevance of extracellular vesicle−lipoprotein complexes remain poorly understood. This Review addresses the current knowledge of the extracellular vesicle−lipoprotein interface while drawing on pre-existing knowledge of liposome interactions with biological nanoparticles. There is an urgent need for further research on the lipoprotein−extracellular vesicle interface, which could return important mechanistic, therapeutic, and diagnostic findings.

show abstract

Section: Interactionsmentioning

confidence: 99%

Section: Lessons Learned From Liposome Interactionsmentioning

confidence: 99%

Extracellular Vesicle and Lipoprotein Interactions

Ghebosu,

Pendiuk Goncalves,

Wolfram

2023

Nano Lett.

View full text Add to dashboard Cite

show abstract

“…[24,25] Liposomes were first developed to encapsulate small-molecule chemotherapies as anticancer therapeutics. [26] The benefits of using LNPs to deliver small molecules are to enhance the therapeutic efficacy by increasing the half-life of active compounds in systemic fluids and targeting tumors through the enhanced permeability and retention (EPR) effect. [27,28] To maintain these advantages, the components of traditional LNPs for small molecule delivery usually contain certain amounts of PEG lipids to prevent the degradation LNPs/drug complex in systemic fluids and to reduce particle size for the EPR effect.…”

Section: Qtplus As An Efficient Platform To Deliver Am21mentioning

confidence: 99%

Antitumor Activity of Anti‐miR‐21 Delivered through Lipid Nanoparticles

Zhang

Huang

Li³

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

The ability of lipid nanoparticles (LNPs) to deliver nucleic acids have shown a great therapeutic potential to treat a variety of diseases. Here, an optimized formulation of QTsome lipid nanoparticles (QTPlus) is utilized to deliver an anti‐miR‐21 (AM21) against cancer. The miR‐21 downstream gene regulation and antitumor activity is evaluated using mouse and human cancer cells and macrophages. The antitumor activity of QTPlus encapsulating AM21 (QTPlus‐AM21) is further evaluated in combination with erlotinib and atezolizumab (ATZ). QTPlus‐AM21 demonstrates a superior miR‐21‐dependent gene regulation and eventually inhibits A549 non‐small cell lung cancer growth in vitro. QTPlus‐AM21 further induces chemo‐sensitization of A549 cells to erlotinib with a combination index of 0.6 in inhibiting A549 cell growth. When systemically administers to MC38 tumor‐bearing mouse model, QTPlus‐AM21 exhibits an antitumor immune response with over 80% tumor growth inhibition (TGI%) and over twofold and fourfold PD‐1 and PD‐L1 upregulation in tumors and spleens. The combination therapy of QTPlus‐AM21 and ATZ further shows a higher antitumor response (TGI% over 90%) and successfully increases M1 macrophages and CD8 T cells into TME. This study provides new insights into the antitumor mechanism of AM21 and shows great promise of QTPlus‐AM21 in combination with chemotherapies and immunotherapies.

show abstract

“…In the 1990s, liposomes took off with the initial clinical trials and the first FDA-approved liposome drug (Doxil ® ). During this period, the discovery of and progress in stealth liposomes also occurred [ 1 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Biomimetic Nanovesicles—Sources, Design, Production Methods, and Applications

et al. 2022

View full text Add to dashboard Cite

Despite all the progress in the field of liposomes and nanoparticles for applications as drug and gene delivery systems, the specific targeting and immune system escape capabilities of these systems are still limited. Biomimetic nanovesicles emerged as a strategy to overcome these and other limitations associated with synthetic carriers, such as short circulation time, cytotoxicity, and difficulty in crossing biological barriers, since many of the desirable abilities of drug delivery systems are innate characteristics of biological vesicles. Thus, the question arises: would biomimetic nanovesicles be responsible for addressing these advances? It is currently known that biomimetic nanovesicles (BNV) can combine the intrinsic advantages of natural materials with the well-known production methods and controllability of synthetic systems. Besides, the development of the biotechnology and nanotechnology fields has provided a better understanding of the functionalities of biological vesicles and the means for the design and production of biomimetic nanovesicles (BNV). Based on this, this work will focus on tracking the main research on biomimetic nanovesicles (BNV) applied as drug and gene delivery systems, and for vaccines applications. In addition, it will describe the different sources of natural vesicles, the technical perspectives on obtaining them, and the possibility of their hybridization with synthetic liposomes.

show abstract

A historical perspective of liposomes-a bio nanomaterial

Cited by 28 publications

References 14 publications

Extracellular Vesicle and Lipoprotein Interactions

Extracellular Vesicle and Lipoprotein Interactions

Antitumor Activity of Anti‐miR‐21 Delivered through Lipid Nanoparticles

Biomimetic Nanovesicles—Sources, Design, Production Methods, and Applications

Contact Info

Product

Resources

About